Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Borderline epithelial ovarian tumours.

A Ayhan1, R Akarin, O Develioglu

  • 1Department of Obstetrics and Gynaecology, Hacettepe University, School of Medicine, Ankara, Turkey.

The Australian & New Zealand Journal of Obstetrics & Gynaecology
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: The HERA (Hyper‑response Risk Assessment) Delphi consensus for the management of hyper‑responders in in vitro fertilization.

Journal of assisted reproduction and genetics·2023
Same author

The HERA (Hyper-response Risk Assessment) Delphi consensus for the management of hyper-responders in in vitro fertilization.

Journal of assisted reproduction and genetics·2023
Same author

The HERA (Hyper-response Risk Assessment) Delphi consensus definition of hyper-responders for in-vitro fertilization.

Journal of assisted reproduction and genetics·2023
Same author

Platelet function testing: dead or alive.

Journal of thrombosis and haemostasis : JTH·2018
Same author

Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2016
Same author

Adjuvant therapy for Stage IA uterine clear cell carcinoma with no myometrial invasion: a critical review of literature.

European journal of gynaecological oncology·2016

Borderline epithelial ovarian tumors are rare. This study found no mortality in Stage 1 borderline ovarian tumors, regardless of treatment, highlighting favorable outcomes for this specific patient group.

Area of Science:

  • Gynecologic Oncology
  • Pathology
  • Clinical Outcomes Research

Background:

  • Borderline epithelial ovarian tumors (BEOTs) represent a unique group of neoplasms with intermediate malignant potential.
  • Understanding the optimal management and prognosis of BEOTs is crucial for patient care.

Purpose of the Study:

  • To evaluate the histopathology, treatment modalities, and outcomes of patients with borderline epithelial ovarian tumors.
  • To assess the survival rates and identify factors influencing prognosis in Stage 1 BEOTs.

Main Methods:

  • Retrospective analysis of 24 patients diagnosed with borderline epithelial ovarian tumors over 12 years.
  • Review of patient data including histopathology, surgical interventions, adjuvant therapies, and clinical outcomes.

Related Experiment Videos

Main Results:

  • No mortality was observed in 23 patients diagnosed with Stage 1 disease.
  • Outcomes remained favorable irrespective of the surgical approach or the use of adjuvant therapy in Stage 1 cases.

Conclusions:

  • Stage 1 borderline epithelial ovarian tumors exhibit a favorable prognosis with no associated mortality in this cohort.
  • Further research may be warranted to fully elucidate the controversial aspects of borderline ovarian tumor management.